Publications

  1. Hoelzinger DB, Dominguez AL, Cohen PA, Gendler SJ. Inhibition of Adaptive Immunity by IL9 Can Be Disrupted to Achieve Rapid T-cell Sensitization and Rejection of Progressive Tumor Challenges. Cancer Res. 2014 Oct 08.
    View PubMed
  2. Northfelt DW, Ramanathan RK, Cohen PA, Von Hoff DD, Weiss GJ, Dietsch GN, Manjarrez KL, Randall TD, Hershberg RM. A Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or Lymphoma. Clin Cancer Res. 2014 Jul 15; 20(14):3683-91. Epub 2014 May 07.
    View PubMed
  3. Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma. Clin Cancer Res. 2014 May 1; 20(9):2457-65. Epub 2014 Mar 14.
    View PubMed
  4. Jaini R, Rayman P, Cohen PA, Finke JH, Tuohy VK. Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy. Int J Cancer. 2014 Apr 1; 134(7):1695-705. Epub 2013 Oct 08.
    View PubMed
  5. Abdel-Aal ABM, Lakshminarayanan V, Thompson P, Supekar N, Bradley JM, Wolfert MA, Cohen PA, Gendler SJ, Boons GJ. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist. ChemBioChem. 2014; 15(10):1508-13.
  6. Poh TW, Madsen CS, Gorman JE, Marler RJ, Leighton JA, Cohen PA, Gendler SJ. Downregulation of hematopoietic MUC1 during experimental colitis increases tumor-promoting myeloid-derived suppressor cells. Clin Cancer Res. 2013 Sep 15; 19(18):5039-52. Epub 2013 Jul 19.
    View PubMed
  7. Finke JH, Rayman PA, Ko JS, Bradley JM, Gendler SJ, Cohen PA. Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics. Cancer J. 2013 Jul-Aug; 19(4):353-64.
    View PubMed
  8. Kottschade LA, Suman VJ, Perez DG, McWilliams RR, Kaur JS, Amatruda TT 3rd, Geoffroy FJ, Gross HM, Cohen PA, Jaslowski AJ, Kosel ML, Markovic SN. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775. Cancer. 2013 Feb 1; 119(3):586-92. Epub 2012 Aug 22.
    View PubMed
  9. Paustian C, Taylor P, Johnson T, Xu M, Ramirez N, Rosenthal KS, Shu S, Cohen PA, Czerniecki BJ, Koski GK. Extracellular ATP and Toll-like receptor 2 agonists trigger in human monocytes an activation program that favors T helper 17. PLoS One. 2013; 8(1):e54804. Epub 2013 Jan 31.
    View PubMed
  10. Zhao X, Bose A, Komita H, Taylor JL, Chi N, Lowe DB, Okada H, Cao Y, Mukhopadhyay D, Cohen PA, Storkus WJ. Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J Immunol. 2012 Feb 15; 188(4):1782-8. Epub 2012 Jan 13.
    View PubMed
  11. Lakshminarayanan V, Thompson P, Wolfert MA, Buskas T, Bradley JM, Pathangey LB, Madsen CS, Cohen PA, Gendler SJ, Boons GJ. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc Natl Acad Sci U S A. 2012 Jan 3; 109(1):261-6. Epub 2011 Dec 14.
    View PubMed
  12. Cohen PA, Ko JS, Storkus WJ, Spencer CD, Bradley JM, Gorman JE, McCurry DB, Zorro-Manrique S, Dominguez AL, Pathangey LB, Rayman PA, Rini BI, Gendler SJ, Finke JH. Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape. Immunol Invest. 2012; 41(6-7):680-710.
    View PubMed
  13. Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, Rini BI, Ko JS, Cohen PA, Finke JH, Storkus WJ. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer. 2011 Nov 1; 129(9):2158-70. Epub 2011 May 25.
    View PubMed
  14. Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol. 2011 Jul; 11(7):856-61. Epub 2011 Feb 11.
    View PubMed
  15. Paustian C, Caspell R, Johnson T, Cohen PA, Shu S, Xu S, Czerniecki BJ, Koski GK. Effect of multiple activation stimuli on the generation of Th1-polarizing dendritic cells. Hum Immunol. 2011 Jan; 72(1):24-31. Epub 2010 Oct 15.
    View PubMed
  16. Lee WT, Tan C, Koski G, Shu S, Cohen P. Immunotherapy using allogeneic squamous cell tumor-dendritic cell fusion hybrids. Head Neck. 2010 Sep; 32(9):1209-16.
    View PubMed
  17. Taylor PR, Koski GK, Paustian CC, Bailey E, Cohen PA, Moore FB, Zimmerman DH, Rosenthal KS. J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells. Vaccine. 2010 Aug 2; 28(34):5533-42. Epub 2010 Jun 25.
    View PubMed
  18. Cho EI, Tan C, Koski GK, Cohen PA, Shu S, Lee WT. Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines. Head Neck. 2010 Jun; 32(6):700-7.
    View PubMed
  19. Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, Rini B, Finke JH, Cohen PA. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 2010 May 1; 70(9):3526-36. Epub 2010 Apr 20.
    View PubMed
  20. Cohen PA, Koski GK, Czerniecki BJ, Bunting KD, Fu XY, Wang Z, Zhang WJ, Carter CS, Awad M, Distel CA, Nagem H, Paustian CC, Johnson TD, Tisdale JF, Shu S. STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells. Blood. 2008 Sep 1; 112(5):1832-43. Epub 2008 Jun 24
    View PubMed
  21. Tamai H, Watanabe S, Zheng R, Deguchi K, Cohen PA, Koski GK, Shu S. Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic-tumor hybrid vaccination and adoptive transfer of sensitized T cells. Clin Immunol. 2008 Apr; 127(1):66-77. Epub 2008 Feb 11.
    View PubMed
  22. Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, Nisenbaum H, Pasha T, Xu M, Fox KR, Weinstein S, Orel SG, Vonderheide R, Coukos G, DeMichele A, Araujo L, Spitz FR, Rosen M, Levine BL, June C, Zhang PJ. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 2007 Feb 15; 67(4):1842-52. Epub 2007 Feb 09.
    View PubMed
  23. Storkus WJ, Herrem C, Kawabe M, Cohen PA, Bukowski RM, Finke JH, Wesa AK. Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes. Crit Rev Immunol. 2007; 27(5):485-93.
    View PubMed
  24. Zheng R, Kjaergaard J, Lee WT, Cohen PA, Shu S. Significance of regional draining lymph nodes in the development of tumor immunity: implications for cancer immunotherapy. Cancer Treat Res. 2007; 135:223-37.
    View PubMed
  25. Shu S, Zheng R, Lee WT, Cohen PA. Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy. Crit Rev Immunol. 2007; 27(5):463-83.
    View PubMed
  26. Kuriyama H, Watanabe S, Kjaergaard J, Tamai H, Zheng R, Weinberg AD, Hu HM, Cohen PA, Plautz GE, Shu S. Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination. Cell Immunol. 2006 Sep; 243(1):30-40. Epub 2007 Jan 17.
    View PubMed
  27. Wang LX, Huang WX, Graor H, Cohen PA, Kim JA, Shu S, Plautz GE. Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+ T cells. J Transl Med. 2004 Nov 26; 2(1):41.
    View PubMed
  28. Koski GK, Kariko K, Xu S, Weissman D, Cohen PA, Czerniecki BJ. Cutting edge: innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells. J Immunol. 2004 Apr 1; 172(7):3989-93.
    View PubMed
  29. Wang LX, Kjaergaard J, Cohen PA, Shu S, Plautz GE. Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy. J Immunol. 2004 Mar 15; 172(6):3462-8.
    View PubMed
  30. Kuriyama H, Shimizu K, Lee W, Kjaergaard J, Parkhurst MR, Cohen PA, Shu S. Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells. Dev Biol (Basel). 2004; 116:169-78; discussion 179-86.
    View PubMed
  31. Bedrosian I, Mick R, Xu S, Nisenbaum H, Faries M, Zhang P, Cohen PA, Koski G, Czerniecki BJ. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol. 2003 Oct 15; 21(20):3826-35.
    View PubMed
  32. Xu S, Koski GK, Faries M, Bedrosian I, Mick R, Maeurer M, Cheever MA, Cohen PA, Czerniecki BJ. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol. 2003 Sep 1; 171(5):2251-61.
    View PubMed
  33. Kjaergaard J, Peng L, Cohen PA, Shu S. Therapeutic efficacy of adoptive immunotherapy is predicated on in vivo antigen-specific proliferation of donor T cells. Clin Immunol. 2003 Jul; 108(1):8-20.
    View PubMed
  34. Plautz GE, Cohen PA, Shu S. Considerations on clinical use of T cell immunotherapy for cancer. Arch Immunol Ther Exp. 2003; 51:245-57.
  35. Peng L, Kjaergäard J, Plautz GE, Awad M, Drazba JA, Shu S, Cohen PA. Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy. J Immunol. 2002 Nov 1; 169(9):4811-21.
    View PubMed
  36. Hayashi T, Tanaka H, Tanaka J, Wang R, Averbook BJ, Cohen PA, Shu S. Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin Immunol. 2002 Jul; 104(1):14-20.
    View PubMed
  37. Lyakh LA, Koski GK, Young HA, Spence SE, Cohen PA, Rice NR. Adenovirus type 5 vectors induce dendritic cell differentiation in human CD14(+) monocytes cultured under serum-free conditions. Blood. 2002 Jan 15; 99(2):600-8.
    View PubMed
  38. Kjaergaard J, Peng L, Cohen PA, Drazba JA, Weinberg AD, Shu S. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J Immunol. 2001 Dec 1; 167(11):6669-77.
    View PubMed
  39. Faries MB, Bedrosian I, Xu S, Koski G, Roros JG, Moise MA, Nguyen HQ, Engels FH, Cohen PA, Czerniecki BJ. Calcium signaling inhibits interleukin-12 production and activates CD83(+) dendritic cells that induce Th2 cell development. Blood. 2001 Oct 15; 98(8):2489-97.
    View PubMed
  40. Koski GK, Lyakh LA, Cohen PA, Rice NR. CD14+ monocytes as dendritic cell precursors: diverse maturation-inducing pathways lead to common activation of NF-kappab/RelB. Crit Rev Immunol. 2001; 21(1-3):179-89.
    View PubMed
  41. Czerniecki BJ, Cohen PA, Faries M, Xu S, Roros JG, Bedrosian I. Diverse functional activity of CD83+ monocyte-derived dendritic cells and the implications for cancer vaccines. Crit Rev Immunol. 2001; 21(1-3):157-78.
    View PubMed
  42. Cohen PA, Peng L, Kjaergaard J, Plautz GE, Finke JH, Koski GK, Czerniecki BJ, Shu S. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance. Crit Rev Immunol. 2001; 21(1-3):215-48.
    View PubMed
  43. Peng L, Krauss JC, Plautz GE, Mukai S, Shu S, Cohen PA. T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-gamma mechanisms that cannot be predicted from in vitro T cell characteristics. J Immunol. 2000 Dec 15; 165(12):7116-24.
    View PubMed
  44. Peng L, Kjaergaard J, Plautz GE, Weng DE, Shu S, Cohen PA. Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression. J Immunol. 2000 Nov 15; 165(10):5738-49.
    View PubMed
  45. Plautz GE, Mukai S, Cohen PA, Shu S. Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors. J Immunol. 2000 Oct 1; 165(7):3656-62.
    View PubMed
  46. Lyakh LA, Koski GK, Telford W, Gress RE, Cohen PA, Rice NR. Bacterial lipopolysaccharide, TNF-alpha, and calcium ionophore under serum-free conditions promote rapid dendritic cell-like differentiation in CD14+ monocytes through distinct pathways that activate NK-kappa B. J Immunol. 2000 Oct 1; 165(7):3647-55.
    View PubMed
  47. Plautz GE, Miller DW, Barnett GH, Stevens GH, Maffett S, Kim J, Cohen PA, Shu S. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res. 2000 Jun; 6(6):2209-18.
    View PubMed
  48. Bedrosian I, Roros JG, Xu S, Nguyen HQ, Engels F, Faries MB, Koski GK, Cohen PA, Czerniecki BJ. Granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin-12 synergize with calcium ionophore to enhance dendritic cell function. J Immunother. 2000 May-Jun; 23(3):311-20.
    View PubMed
  49. Podrez EA, Febbraio M, Sheibani N, Schmitt D, Silverstein RL, Hajjar DP, Cohen PA, Frazier WA, Hoff HF, Hazen SL. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest. 2000 Apr; 105(8):1095-108.
    View PubMed
  50. Cohen PA, Peng L, Plautz GE, Kim JA, Weng DE, Shu S. CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit Rev Immunol. 2000; 20(1):17-56.
    View PubMed
  51. Hazen SL, Zhang R, Shen Z, Wu W, Podrez EA, MacPherson JC, Schmitt D, Mitra SN, Mukhopadhyay C, Chen Y, Cohen PA, Hoff HF, Abu-Soud HM. Formation of nitric oxide-derived oxidants by myeloperoxidase in monocytes: pathways for monocyte-mediated protein nitration and lipid peroxidation In vivo. Circ Res. 1999 Nov 12; 85(10):950-8.
    View PubMed
  52. Engels FH, Koski GK, Bedrosian I, Xu S, Luger S, Nowell PC, Cohen PA, Czerniecki BJ. Calcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cells. Proc Natl Acad Sci U S A. 1999 Aug 31; 96(18):10332-7.
    View PubMed
  53. Koski GK, Schwartz GN, Weng DE, Gress RE, Engels FH, Tsokos M, Czerniecki BJ, Cohen PA. Calcium ionophore-treated myeloid cells acquire many dendritic cell characteristics independent of prior differentiation state, transformation status, or sensitivity to biologic agents. Blood. 1999 Aug 15; 94(4):1359-71.
    View PubMed
  54. Koski GK, Schwartz GN, Weng DE, Czerniecki BJ, Carter C, Gress RE, Cohen PA. Calcium mobilization in human myeloid cells results in acquisition of individual dendritic cell-like characteristics through discrete signaling pathways. J Immunol. 1999 Jul 1; 163(1):82-92.
    View PubMed
  55. Plautz GE, Weng DE, Kim JA, Cohen PA, Shu S. Preclinical development and clinical experience with T cell adoptive immunotherapy of cancer. Recent Res Devel Cancer. 1999; 1:163-79.
  56. Czerniecki BJ, Carter C, Rivoltini L, Koski GK, Kim HI, Weng DE, Roros JG, Hijazi YM, Xu S, Rosenberg SA, Cohen PA. Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells. J Immunol. 1997 Oct 15; 159(8):3823-37.
    View PubMed
  57. Jakobsen MK, Restifo NP, Cohen PA, Marincola FM, Cheshire LB, Linehan WM, Rosenberg SA, Alexander RB. Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line. J Immunother Emphasis Tumor Immunol. 1995 May; 17(4):222-8.
    View PubMed
  58. Alexander RB, Fitzgerald EB, Mixon A, Carter CS, Jakobsen M, Cohen PA, Rosenberg SA. Helper T cells infiltrating human renal cell carcinomas have the phenotype of activated memory-like T lymphocytes. J Immunother Emphasis Tumor Immunol. 1995 Jan; 17(1):39-46.
    View PubMed
  59. Marincola FM, Ettinghausen S, Cohen PA, Cheshire LB, Restifo NP, Mule JJ, Rosenberg SA. Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-alpha. J Immunol. 1994 Apr 1; 152(7):3500-13.
    View PubMed
  60. Cohen PA, Cohen PJ, Rosenberg SA, Mule JJ. CD4+ T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens. Cancer Res. 1994 Feb 15; 54(4):1055-8.
    View PubMed
  61. Fowler DH, Kurasawa K, Husebekk A, Cohen PA, Gress RE. Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. Regulation of cytokines and CD8+ lymphoid engraftment. J Immunol. 1994 Feb 1; 152(3):1004-13.
    View PubMed
  62. Cohen PJ, Cohen PA, Rosenberg SA, Katz SI, Mule JJ. Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells. Eur J Immunol. 1994 Feb; 24(2):315-9.
    View PubMed
  63. Cohen PA, Kim H, Fowler DH, Gress RE, Jakobsen MK, Alexander RB, Mule JJ, Carter C, Rosenberg SA. Use of interleukin-7, interleukin-2, and interferon-gamma to propagate CD4+ T cells in culture with maintained antigen specificity. J Immunother Emphasis Tumor Immunol. 1993 Oct; 14(3):242-52.
    View PubMed
  64. Chen PP, Nonaka M, O'Hair CH, Cohen PA, Zuraw BL, Katz DH. Human IgE synthesis in vitro by pokeweed mitogen-stimulated human lymphoid cells: verification with a reconfirmed epsilon-specific radioimmunoassay. J Immunol. 1984 Oct; 133(4):1909-13.
    View PubMed